Treatment options for patients with Venous Thromboembolism (VTE), or blood clots in the veins, include warfarin and direct oral anticoagulants (DOACs). Researchers studied a survey of adults, from two large integrated health systems, who took DOACs or warfarin for VTE over a period of time. The study, co-authored by Kristi Reynolds, PhD, MPH, Director of Epidemiologic Research for Kaiser Permanente Southern California, and Alan S. Go, MD, Regional Director of Kaiser Permanente Northern California Clinical Trials Program, found greater treatment satisfaction among patients taking DOACs. Their findings may help clinicians inform patients of the comparative differences between these two anticoagulant options. Both Reynolds and Go are KPSOM research mentors and professors.
From Journal of Thrombosis and Thrombolysis:
A closer look at blood clot treatments
Study shows differences in satisfaction between warfarin and direct oral anticoagulants (DOACs)
